LEGEND Raises $140.1M, Cash Reserves Reach $342.4M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
As of October 31, 2025, cash, cash equivalents and marketable securities were $202.3 million. An additional $140.1 million in net proceeds was raised during a public offering in November. The Company expects that its cash and cash equivalents together with the net proceeds from the November financing will fund operating expenses, debt obligations and capital expenditures into the second half of 2028. "We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved," said Ron Cooper, President and Chief Executive Officer. "With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in preparation for our planned BLA filing in the second half of 2026 and a potential approval in 2027."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ENGN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ENGN
Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 23.75 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.200
Low
10.00
Averages
23.75
High
33.00
Current: 10.200
Low
10.00
Averages
23.75
High
33.00
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
enGene Holdings Inc. (ENGN) Expands $125M Debt Facility, Stock Rises 14%
- Stock Surge: enGene Holdings Inc. saw a 14% increase in stock price on Friday, closing at $12.12, which is a $1.48 gain from the previous session, reflecting strong market confidence in its financial health.
- Debt Facility Expansion: The company announced an expanded $125 million debt facility with Hercules Capital, Inc., which includes $100 million in new loan proceeds and $25 million to refinance existing debt, enhancing its financial flexibility.
- Strong Market Performance: ENGN's stock has risen in eight of the past nine trading sessions, climbing approximately 47% since January 6, and reached a new 52-week high of $12.25 on Friday, indicating investor optimism about its future potential.
- Clear Future Plans: CEO Ron Cooper stated that the additional capital will support the company's plans for a BLA filing in the second half of this year and a potential commercial launch in 2027, showcasing its strategic positioning in the gene therapy sector.
Continue Reading
enGene Holdings Secures $125 Million Loan Agreement with Hercules Capital
- Financing Enhancement: enGene has entered into an amended loan agreement with Hercules Capital for up to $125 million in non-dilutive capital, strengthening the company's financial flexibility in preparation for its planned Biologics License Application (BLA) to the FDA in the second half of 2026.
- Clinical Trial Support: The loan agreement includes an initial $25 million for refinancing existing debt, with an additional $75 million available based on clinical and regulatory milestones, ensuring continued R&D in high-risk non-muscle invasive bladder cancer (NMIBC) treatment.
- Significant Market Potential: Approximately 75-80% of new bladder cancer diagnoses are NMIBC, with BCG-unresponsive patients facing a 50-70% recurrence rate, making enGene's detalimogene voraplasmid a promising innovative bladder-sparing treatment option to meet urgent market needs.
- Deepening Strategic Partnership: Hercules Capital's support underscores its commitment as a long-term capital partner and highlights the importance of financing innovative life sciences companies, aiding enGene in the potential commercial launch of detalimogene in 2027.
Continue Reading